Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsed or Refractory Follicular Lymphoma Clear all
Terminated Phase 1Phase 2 Interventional Results available

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

NCT04358458
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Interventions
GEN3009, Epcoritamab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Denver, Colorado • Cleveland, Ohio • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00022581
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
thalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
View directory record Official record
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

NCT04447716
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
Interventions
Venetoclax, Lenalidomide, Rituximab, Rituximab and Hyaluronidase Human
Drug · Biological
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 10:12 PM EDT
No Longer Available No phase listed Expanded access

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00423826
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

NCT00060684
View directory record Official record
Conditions
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
Interventions
Pixantrone (BBR 2778), fludarabine, dexamethasone, rituximab
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
4
States / cities
Tucson, Arizona • Baltimore, Maryland • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02611323
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Rituximab, Polatuzumab Vedotin, Venetoclax
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • New Haven, Connecticut • Pembroke, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

NCT05665062
View directory record Official record
Conditions
CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Interventions
SYNCAR-001, STK-009, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
4
States / cities
Duarte, California • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

NCT02187861
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Bendamustine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

NCT02413489
View directory record Official record
Conditions
Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Duarte, California • Fountain Valley, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

NCT00372905
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, Ibritumomab tiuxetan
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
Odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
13
States / cities
Chicago, Illinois • Iowa City, Iowa • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 10:12 PM EDT
Recruiting Phase 1 Interventional

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

NCT04775745
View directory record Official record
Conditions
CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Interventions
LP-168
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553
View directory record Official record
Conditions
Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Blinatumomab, Lenalidomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 3 Interventional

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

NCT00060671
View directory record Official record
Conditions
Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Low-Grade
Interventions
rituximab, Pixantrone (BBR 2778)
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
38
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00086944
View directory record Official record
Conditions
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
oblimersen sodium, rituximab, ifosfamide, carboplatin, etoposide, filgrastim, pegfilgrastim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
Drug · Combination Product
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
57
States / cities
Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Lenalidomide, Valemetostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 23, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

NCT00479167
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Bortezomib and Tositumomab I-131
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Results available

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

NCT02669017
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma
Interventions
ADCT-402
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 23, 2026, 10:12 PM EDT
Completed Early Phase 1 Interventional

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT01719250
View directory record Official record
Conditions
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Interventions
Buparlisib, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Jul 23, 2026, 10:12 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
tafasitamab, rituximab, lenalidomide, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
38
States / cities
Concord, California • Greenbrae, California • Pasadena, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 23, 2026, 10:12 PM EDT